JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB5401

Anti-RNA polymerase II CTD repeat YSPTSPS (phospho S5) antibody [8A7]

4

(6 Reviews)

|

(11 Publications)

Mouse Monoclonal RNA polymerase II RPB1 phospho S5 antibody. Suitable for Flow Cyt and reacts with Human samples. Cited in 11 publications. Immunogen corresponding to Synthetic Peptide within Human POLR2A phospho S5.

View Alternative Names

POLR2, POLR2A, DNA-directed RNA polymerase II subunit RPB1, RNA polymerase II subunit B1, 3'-5' exoribonuclease, DNA-directed RNA polymerase II subunit A, DNA-directed RNA polymerase III largest subunit, RNA-directed RNA polymerase II subunit RPB1

1 Images
Flow Cytometry - Anti-RNA polymerase II CTD repeat YSPTSPS (phospho S5) antibody [8A7] (AB5401)
  • Flow Cyt

Unknown

Flow Cytometry - Anti-RNA polymerase II CTD repeat YSPTSPS (phospho S5) antibody [8A7] (AB5401)

Overlay histogram showing HeLa (Human epithelial cell line from cervix adenocarcinoma) cells stained with ab5401 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab5401, 1μg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2μg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

8A7

Isotype

IgG1

Carrier free

No

Reacts with

Human

Applications

Flow Cyt

applications

Immunogen

Synthetic Peptide within Human POLR2A phospho S5. The exact immunogen used to generate this antibody is proprietary information.

P24928

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1 µg for 10^6 Cells", "FlowCyt-species-notes": "<p><a href='/en-us/products/primary-antibodies/mouse-igg1-kappa-monoclonal-15-6e10a7-isotype-control-ab170190'>ab170190</a> - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.</p>" }, "Mouse": { "FlowCyt-species-checked": "predicted", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
Preservative: 0.02% Sodium azide Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

RNA polymerase II CTD repeat YSPTSPS also known as the C-terminal domain of RNA polymerase II is a critical component of the RNA polymerase II enzyme commonly referred to as pol II. This domain is characterized by the repetitive sequence YSPTSPS which plays a significant role in the regulation of transcription. The mass of RNA polymerase II including its CTD varies but is essential for its function in gene expression. RNA polymerase II with the CTD is expressed in the nucleus of eukaryotic cells where it orchestrates the transcription of DNA into mRNA.
Biological function summary

RNA polymerase II CTD repeat YSPTSPS is essential for the transcription progression from initiation to termination. It is part of the large RNA polymerase II complex interacting with various transcription factors and enzymes necessary for RNA processing. The phosphorylation state of the CTD particularly on serine residues regulates interactions with splicing machinery and other RNA processing factors. This modulation ensures the coupling between transcription and RNA processing events controlling mRNA synthesis and maturation.

Pathways

RNA polymerase II CTD repeat YSPTSPS is important in the mRNA synthesis pathway specifically in transcriptional regulation and processing of nascent RNA transcripts. It interacts with proteins such as the transcription factors TFIIH and TFIIB which aid in promoter recognition and open complex formation. The CTD's dynamic phosphorylation pattern allows integration into multiple cellular pathways most importantly connecting transcription with RNA splicing and transport pathways.

Abnormal function or mutations in RNA polymerase II CTD repeat YSPTSPS associate with diseases such as transcription-related syndromes and certain cancers. Deficient CTD phosphorylation can lead to improper mRNA processing resulting in neural developmental disorders. Additionally its interaction with proteins like CDK7 which phosphorylates the CTD links it to tumors where transcriptional dysregulation is a hallmark. Understanding the CTD's role in these diseases provides insight into therapeutic targets and strategies for intervention.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed : 23748380, PubMed : 27193682, PubMed : 30190596, PubMed : 9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed : 23748380, PubMed : 27193682, PubMed : 28108474, PubMed : 30190596, PubMed : 9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed : 30190596, PubMed : 8381534, PubMed : 9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed : 8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed : 24207025, PubMed : 26124092).. RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription.. (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome.
See full target information POLR2A phospho S5

Publications (11)

Recent publications for all applications. Explore the full list and refine your search

British journal of cancer 128:2326-2337 PubMed37076563

2023

The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Theodora A Constantin,Anabel Varela-Carver,Kyle K Greenland,Gilberto Serrano de Almeida,Ellen Olden,Lucy Penfold,Simon Ang,Alice Ormrod,Damien A Leach,Chun-Fui Lai,Edward K Ainscow,Ash K Bahl,David Carling,Matthew J Fuchter,Simak Ali,Charlotte L Bevan

Molecular cancer 21:82 PubMed35317841

2022

A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.

Applications

Unspecified application

Species

Unspecified reactive species

C E Fletcher,L Deng,F Orafidiya,W Yuan,M P G S Lorentzen,O W Cyran,A Varela-Carver,T A Constantin,D A Leach,F M Dobbs,I Figueiredo,B Gurel,E Parkes,D Bogdan,R R Pereira,S G Zhao,A Neeb,F Issa,J Hester,H Kudo,Y Liu,Y Philippou,R Bristow,K Knudsen,R J Bryant,F Y Feng,S H Reed,I G Mills,J de Bono,C L Bevan

PloS one 12:e0180141 PubMed28704378

2017

Characterizing properties of non-estrogenic substituted bisphenol analogs using high throughput microscopy and image analysis.

Applications

Unspecified application

Species

Unspecified reactive species

Adam T Szafran,Fabio Stossi,Maureen G Mancini,Cheryl L Walker,Michael A Mancini

The Journal of investigative dermatology 136:473-480 PubMed26967480

2016

Symptomatic Improvement in Human Papillomavirus-Induced Epithelial Neoplasia by Specific Targeting of the CXCR4 Chemokine Receptor.

Applications

Unspecified application

Species

Unspecified reactive species

Floriane Meuris,Françoise Gaudin,Marie-Laure Aknin,Patrice Hémon,Dominique Berrebi,Françoise Bachelerie

Molecular endocrinology (Baltimore, Md.) 30:158-72 PubMed26652902

2015

Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK.

Applications

Unspecified application

Species

Unspecified reactive species

Lindsey S Treviño,Michael J Bolt,Sandra L Grimm,Dean P Edwards,Michael A Mancini,Nancy L Weigel

Chemistry & biology 21:743-53 PubMed24856822

2014

Defining estrogenic mechanisms of bisphenol A analogs through high throughput microscopy-based contextual assays.

Applications

Unspecified application

Species

Unspecified reactive species

Fabio Stossi,Michael J Bolt,Felicity J Ashcroft,Jane E Lamerdin,Jonathan S Melnick,Reid T Powell,Radhika D Dandekar,Maureen G Mancini,Cheryl L Walker,John K Westwick,Michael A Mancini

Oncogene 34:154-64 PubMed24441042

2014

Systems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-α protein levels and activity.

Applications

Unspecified application

Species

Human

M J Bolt,F Stossi,A M Callison,M G Mancini,R Dandekar,M A Mancini

Proceedings of the National Academy of Sciences of 111:2247-52 PubMed24390544

2014

The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition.

Applications

Unspecified application

Species

Unspecified reactive species

Pamela V Chang,Liming Hao,Stefan Offermanns,Ruslan Medzhitov

Nucleic acids research 41:4036-48 PubMed23444138

2013

Coactivators enable glucocorticoid receptor recruitment to fine-tune estrogen receptor transcriptional responses.

Applications

ICC

Species

Unspecified reactive species

Michael J Bolt,Fabio Stossi,Justin Y Newberg,Arturo Orjalo,Hans E Johansson,Michael A Mancini

Journal of medicinal chemistry 49:6500-9 PubMed17064068

2006

4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.

Applications

WB

Species

Human

Vladimír Krystof,Petr Cankar,Iveta Frysová,Jan Slouka,George Kontopidis,Petr Dzubák,Marián Hajdúch,Josef Srovnal,Walter F de Azevedo,Martin Orság,Martina Paprskárová,Jakub Rolcík,Ales Látr,Peter M Fischer,Miroslav Strnad
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com